Table 1 Study participants.

From: Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction

Sample ID

Age (years, as of 2019)

Gender

Smoking history (pack—year)

Group

Lung-RAD Score

Death Cancer Related

Initial

latest

82

62

M

40

A

2

4A

None

83

64

F

40

A

2

2

None

84

62

F

45

A

2

2

None

85

62

F

30

A

2

2

None

88

45

F

80

A

2

2

None

91

51

F

40

A

2

2

None

96

58

F

45

A

2

2

None

98

56

F

45

A

2

2

None

99

60

M

35

A

2

2

None

100

61

F

30

A

2

4A

None

102

53

F

40

A

2

2

None

104

58

M

50

A

2

2

None

105

53

F

80

A

2

2

None

106

48

M

45

A

2

2

None

111

57

F

60

A

2

2

None

114

61

M

30

A

2

3

None

120

63

F

40

A

2

4A

None

121

57

F

90

A

2

3

None

123

50

F

40

A

2

2

None

124

61

M

50

A

2

2

None

8

50

F

100

B

4

4B

None

12

50

F

55

B

4

4X

None

15

56

F

45

B

4

4B

None

16

42

F

40

B

4

4B

None

30

49

F

55

B

4

4A

Yes

40

55

M

45

B*

4

4B

None

52

44

F

50

B

4

4B

None

53

58

M

27

B

4

4B

None

70

45

M

50

B

4

4X

None

92

61

M

40

B*

4

4A

None

115

51

F

40

B

4

4B

None

135

50

M

25

B*

4

4B/4X

None

138

49

F

100

B

4

4X

Yes

139

52

F

40

B*

4

4A

None

149

57

M

40

B*

4

4B

None

152

49

F

25

B

4

4B

None

159

60

M

60

B

4

4B

None

170

53

F

40

B

4

4B

None

171

55

M

80

B*

4

2

None

183

56

F

40

B

4

4X

None

  1. Table showing each patient’s description including, age, gender, smoking history, and cancer progression status. False positive diagnoses are denoted with an asterisk (*) in the Group column. Group A and B contain individuals with lung-RADS2 or lung-RADS4 initial LDCT findings, respectively.